We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current HALO market cap is 7.27B. The company's latest EPS is USD 3.6060 and P/E is 16.30.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 230.04M | 195.88M | 231.35M | 290.08M | 298.01M |
| Operating Income | 101.04M | 95.54M | 117.24M | 163.2M | 175.5M |
| Net Income | 85.39M | 76.82M | 93.25M | 137.01M | 137.01M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 267.59M | 443.31M | 660.12M | 829.25M | 1.02B |
| Operating Income | 144.26M | 275.9M | 267.53M | 337.57M | 551.48M |
| Net Income | 129.09M | 402.71M | 202.13M | 281.59M | 444.09M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 1.73B | 1.84B | 1.97B | 2.12B | 2.06B |
| Total Liabilities | 1.65B | 1.66B | 1.68B | 1.67B | 1.7B |
| Total Equity | 83.81M | 177.81M | 289.42M | 452.7M | 363.82M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 579.92M | 1.1B | 1.84B | 1.73B | 2.06B |
| Total Liabilities | 428.88M | 907.48M | 1.67B | 1.65B | 1.7B |
| Total Equity | 151.05M | 196.95M | 169.8M | 83.81M | 363.82M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 388.57M | 129.43M | 185.22M | 300.6M | 479.06M |
| Investing | -96.91M | -82.68M | -124.72M | -292.2M | -262.72M |
| Financing | -407.99M | -489k | 8.99M | 27.55M | -218.86M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 55.45M | 299.44M | 240.11M | 388.57M | 479.06M |
| Investing | 78.35M | -406.29M | -487.01M | -96.91M | -262.72M |
| Financing | -106.28M | 77.87M | 362.37M | -407.99M | -218.86M |
| Market Cap | 7.27B |
| Price to Earnings Ratio | 16.30 |
| Price to Sales Ratio | 7.13 |
| Price to Cash Ratio | 62.49 |
| Price to Book Ratio | 19.9 |
| Dividend Yield | - |
| Shares Outstanding | 123.15M |
| Average Volume (1 week) | 1.68M |
| Average Volume (1 Month) | 1.8M |
| 52 Week Change | 53.45% |
| 52 Week High | 66.00 |
| 52 Week Low | 37.73 |
| Spread (Intraday) | 5.6 (8.89%) |
| Company Name | Halozyme Therapeutics Incorporated |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.halozyme.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
